MK-677 (Ibutamoren) + GHK-Cu Stack: Complete Protocol

What Are MK-677 and GHK-Cu, and Why Stack Them?

MK-677 (ibutamoren) drives pulsatile growth hormone (GH) release by mimicking ghrelin at the GH secretagogue receptor, raising serum IGF-1 without exogenous GH injections. GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine complexed with copper 2+) that peaks in human plasma around age 20 and declines to roughly one-third of that level by age 60. Stacking them targets the GH/IGF-1 axis for systemic anabolism while GHK-Cu acts on local tissue repair, collagen remodeling, and antioxidant signaling.

The rationale is complementary biology, not redundancy. MK-677 lifts the systemic anabolic tide. GHK-Cu provides a localized tissue-renewal signal that IGF-1 alone does not fully replicate.

MK-677 Mechanism

MK-677 binds the ghrelin receptor (GHSR-1a) in the hypothalamus and pituitary, amplifying endogenous GH pulses rather than replacing them. A 2-year randomized controlled trial in 65 hip-fracture patients showed that 25 mg/day of MK-677 increased serum IGF-1 by 84% above baseline and improved functional recovery scores compared to placebo [1]. A separate 12-month trial (N=32) in older adults with low IGF-1 documented a sustained 60% rise in IGF-1 with 25 mg daily [2]. Because secretion remains pulsatile, the GH/cortisol ratio stays more physiological than with exogenous GH injections.

GHK-Cu Mechanism

GHK-Cu was first isolated from human plasma in 1973 by Loren Pickart. The peptide upregulates roughly 31 genes involved in collagen and glycosaminoglycan synthesis while downregulating 36 genes linked to inflammation and tumor promotion, based on Affymetrix gene-array data reviewed by Pickart and Margolina [3]. It also activates superoxide dismutase (SOD), a primary endogenous antioxidant enzyme, via copper chaperoning. These tissue-level effects operate independently of the GH/IGF-1 axis.

Evidence for Each Compound Separately

MK-677 Clinical Data

The strongest human data on MK-677 comes from Merck-sponsored studies from the late 1990s through early 2000s, several of which were published in peer-reviewed journals.

A 1998 NEJM trial by Chapman et al. (N=395, 2 years) found that 25 mg/day MK-677 increased lean body mass by 1.0 to 2.0 kg compared to placebo in adults aged 60 to 81, with statistically significant IGF-1 elevation throughout the study period [4]. The compound was orally active, which distinguishes it from injectable GH secretagogues like sermorelin or CJC-1295.

Fasting glucose rose by approximately 0.3 mmol/L (5.4 mg/dL) versus placebo in that trial, a finding that has been replicated in subsequent work [4]. Prolactin increased modestly in some participants. These safety signals are relevant when selecting candidates for a stack.

GHK-Cu Human Data

GHK-Cu has been studied primarily in wound healing and dermatology contexts. A double-blind trial published in the Journal of the American Academy of Dermatology found that a 1% GHK-Cu cream applied twice daily for 12 weeks produced statistically significant improvements in skin density, thickness, and fine-line depth compared to vehicle control [5]. Systemic subcutaneous administration at doses up to 2 mg/day has not produced serious adverse events in reported Phase I and Phase II studies, though large-scale safety trials are absent from the published literature.

Animal data are more extensive. A rat wound-healing model showed that GHK-Cu at 1 mg/kg/day accelerated full-thickness wound closure by 30% versus saline control, associated with increased collagen III deposition on histology [6].

Rationale for Combining MK-677 and GHK-Cu

These two compounds address different biological targets, which is the primary justification for combining them.

Systemic vs. Local Signaling

MK-677 raises circulating IGF-1, which drives systemic protein synthesis, lean mass accrual, and GH-dependent lipolysis. GHK-Cu acts at the tissue level through cell-surface receptor interactions and intracellular copper delivery; it does not depend on IGF-1 signaling to stimulate collagen or SOD upregulation [3]. A person using MK-677 for body composition or recovery who also wants improved skin texture, connective tissue health, or wound repair gains additive biology from GHK-Cu without pharmacological competition between the two agents.

Shared Downstream Target: Collagen

Both compounds influence collagen, but by different routes. IGF-1 (elevated by MK-677) stimulates fibroblast proliferation and procollagen mRNA transcription [7]. GHK-Cu directly upregulates collagen I, III, and elastin gene expression in fibroblasts independent of growth factor signaling [3]. Combining them may produce additive collagen support, though no direct head-to-head or combination human trial has tested this hypothesis.

Anti-Aging and Recovery Context

In the context of age-related decline, MK-677 addresses the well-documented fall in GH pulsatility after age 40 (GH secretion declines roughly 14% per decade in adults [8]). GHK-Cu addresses the parallel fall in plasma GHK-Cu concentrations that accompanies aging. Using both compounds together is, mechanistically, an attempt to restore two separate age-related deficits simultaneously.

Complete Stack Protocol

The protocol below synthesizes manufacturer dosing guidance, published clinical trial doses, and practitioner-reported clinical experience. No RCT has validated this specific combination. Review with a physician before initiating either compound.

Phase 1: Baseline Assessment (Weeks -2 to 0)

Before starting, obtain:

• Fasting glucose and HbA1c (MK-677 can worsen insulin resistance)
• Fasting insulin and HOMA-IR
• Serum IGF-1 (morning, fasting)
• Complete metabolic panel including liver enzymes
• Prolactin
• Fasting lipid panel
• For topical GHK-Cu: a baseline clinical photo series of target skin area

Patients with fasting glucose above 100 mg/dL, active diabetes, or elevated prolactin should discuss risks explicitly with their prescribing clinician before proceeding with MK-677.

Phase 2: Ramp-Up (Weeks 1-4)

MK-677: Begin at 10 mg orally each evening, 30 to 60 minutes before bed. Nighttime dosing aligns GH release with the natural nocturnal GH surge and may reduce daytime hunger side effects. After 2 weeks, titrate to 25 mg nightly if the 10 mg dose is tolerated without significant water retention, morning lethargy, or hunger dysregulation.

GHK-Cu (subcutaneous route): Start at 0.5 mg subcutaneously once daily, injected into subcutaneous abdominal or thigh tissue. After one week without local reactions, advance to 1 mg daily. Injections at any time of day are acceptable; morning administration is common in practice.

GHK-Cu (topical route): Apply a 2 to 5% GHK-Cu formulation to target skin areas once or twice daily after cleansing. Topical GHK-Cu is generally considered safer for self-administration and does not require blood monitoring specific to the peptide itself.

Phase 3: Maintenance (Weeks 5-16)

• MK-677: 25 mg nightly (some patients prefer 12.5 mg if hunger or water retention is problematic)
• GHK-Cu: 1 to 2 mg subcutaneously daily, or continued topical application
• Recheck IGF-1, fasting glucose, prolactin, and liver enzymes at week 8

Target IGF-1 range during MK-677 use: 200 to 350 ng/mL (age-adjusted). IGF-1 above 350 ng/mL in adults warrants dose reduction to limit theoretical long-term proliferative risk [9].

Phase 4: Off-Cycle (Weeks 17-24)

Discontinue MK-677 after 12 to 16 weeks. IGF-1 returns toward baseline within 4 to 6 weeks of stopping. GHK-Cu may be continued through the off-cycle given its favorable safety profile, though some practitioners prefer a full rest period. Recheck labs 4 weeks after stopping MK-677 to confirm IGF-1 normalization and glucose return to pre-cycle values.

Dosing Reference Table

| Compound | Route | Starting Dose | Maintenance Dose | Timing | |---|---|---|---|---| | MK-677 | Oral | 10 mg/day | 25 mg/day | Nightly, 30 to 60 min before sleep | | GHK-Cu | Subcutaneous | 0.5 mg/day | 1 to 2 mg/day | Any time; morning common | | GHK-Cu | Topical | 1% cream | 2 to 5% cream/serum | Once or twice daily after cleanse |

Safety Profile and Contraindications

MK-677 Safety

The most common adverse effects from the Chapman et al. Trial (N=395) were increased appetite (reported by 21% of participants), peripheral edema (16%), and mild fasting hyperglycemia [4]. Joint pain related to GH-induced fluid shifts occurs in a subset of users, particularly at 25 mg. Prolactin elevation is mild and usually asymptomatic, but pre-existing hyperprolactinemia is a relative contraindication.

MK-677 is contraindicated in active malignancy. IGF-1 is a mitogen, and chronically supraphysiologic levels carry theoretical proliferative risk [9]. Patients with a personal or first-degree family history of IGF-1-sensitive cancers (breast, colon, prostate) should have an individualized risk discussion with their physician before use.

GHK-Cu Safety

GHK-Cu has no established serious adverse effects at doses studied in humans. Copper toxicity is not reported at the microgram-to-milligram doses used in peptide protocols; total daily copper intake from 2 mg GHK-Cu represents a fraction of the 900 mcg/day Recommended Dietary Allowance for copper [10]. Local injection-site reactions (mild erythema, transient swelling) are the most frequently reported issues.

Topical GHK-Cu is generally well tolerated even in people with sensitive skin, though blue-green staining from copper oxidation can occur on some fabric or porous surfaces.

Drug Interactions

No formal pharmacokinetic interaction studies exist for this combination. MK-677 is metabolized primarily through CYP3A4; potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may raise MK-677 plasma concentrations. GHK-Cu has no known significant drug interactions. Both compounds should be used with caution alongside insulin or sulfonylureas given MK-677's glucose-elevating effect.

Who May Benefit From This Stack

Practitioners and patients most commonly discuss this combination in three clinical contexts:

Body composition and lean mass. Adults aged 35 and older experiencing age-related declines in GH pulsatility and IGF-1 who want to support lean mass preservation without injectable GH. MK-677 provides the primary anabolic signal; GHK-Cu supports connective tissue resilience during resistance training.

Skin and connective tissue health. Individuals prioritizing collagen density, wound repair, or skin texture alongside a body composition protocol. The 1% GHK-Cu cream trial showing statistically significant skin density improvements at 12 weeks [5] supports topical use as an accessible entry point.

Post-injury recovery. Athletes or patients recovering from soft-tissue injuries may benefit from IGF-1 elevation through MK-677 plus the localized collagen-stimulating effects of GHK-Cu at the injury site. Animal data support GHK-Cu's role in accelerated wound closure [6], though human orthopedic RCT data are absent.

Evidence Gaps and Limitations

Be direct: this stack has not been tested as a combination in any published randomized controlled trial. Every claim about the two compounds together is extrapolated from their individual pharmacology and mechanistic data. The following gaps are material:

• No pharmacokinetic interaction data confirm that oral MK-677 and subcutaneous GHK-Cu do not alter each other's exposure.
• No human trial has measured collagen outcomes when both compounds are used simultaneously.
• Long-term IGF-1 elevation above the physiological range carries theoretical oncogenic risk that has not been resolved by any life-span outcome trial.
• GHK-Cu's systemic bioavailability from subcutaneous injection vs. Topical application has not been rigorously quantified in humans.

The Endocrine Society's 2019 Clinical Practice Guideline on GH deficiency in adults states: "We recommend against the use of GH or GH secretagogues in adults without biochemically confirmed GH deficiency" [11]. That guidance applies directly to MK-677 used for body composition in GH-sufficient individuals and should be disclosed to all patients.

Monitoring Schedule Summary

| Timepoint | Labs | |---|---| | Baseline (Week -2) | IGF-1, fasting glucose, HbA1c, insulin, HOMA-IR, CMP, prolactin, lipid panel | | Week 8 | IGF-1, fasting glucose, prolactin, liver enzymes | | End of cycle (Week 16) | Full repeat of baseline panel | | Off-cycle (Week 20) | IGF-1, fasting glucose (confirm normalization) |